| Code | CSB-RA868278MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to ORKA-001, designed for research targeting IL23A (Interleukin-23 subunit alpha), also known as p19. IL23A combines with IL12B to form the heterodimeric cytokine IL-23, which plays a critical role in inflammatory and immune responses by promoting the differentiation and survival of Th17 cells. IL-23 signaling is central to the pathogenesis of various autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, inflammatory bowel disease, and ankylosing spondylitis. Elevated IL-23 levels have been implicated in chronic inflammation and tissue damage associated with these disorders.
ORKA-001 represents a therapeutic antibody class that selectively targets the IL23A subunit, preventing IL-23 formation and subsequent downstream inflammatory cascades. This biosimilar provides researchers with a valuable tool for investigating IL-23-mediated immune mechanisms, studying autoimmune disease pathology, evaluating therapeutic intervention strategies, and exploring the role of Th17 cells in inflammation. The antibody enables detailed examination of IL-23 biology in various experimental models and supports translational research in immunology and inflammatory disease.
There are currently no reviews for this product.